154 related articles for article (PubMed ID: 31520135)
1. Ligandomes obtained from different HLA-class II-molecules are homologous for N- and C-terminal residues outside the peptide-binding cleft.
Kampstra ASB; van Heemst J; Janssen GM; de Ru AH; van Lummel M; van Veelen PA; Toes REM
Immunogenetics; 2019 Sep; 71(8-9):519-530. PubMed ID: 31520135
[TBL] [Abstract][Full Text] [Related]
2. Sampling From the Proteome to the Human Leukocyte Antigen-DR (HLA-DR) Ligandome Proceeds Via High Specificity.
Mommen GP; Marino F; Meiring HD; Poelen MC; van Gaans-van den Brink JA; Mohammed S; Heck AJ; van Els CA
Mol Cell Proteomics; 2016 Apr; 15(4):1412-23. PubMed ID: 26764012
[TBL] [Abstract][Full Text] [Related]
3. Analysis of MHC class II antigen processing by quantitation of peptides that constitute nested sets.
Lippolis JD; White FM; Marto JA; Luckey CJ; Bullock TN; Shabanowitz J; Hunt DF; Engelhard VH
J Immunol; 2002 Nov; 169(9):5089-97. PubMed ID: 12391225
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the HLA-DR peptidome from human dendritic cells reveals high affinity repertoires and nonconventional pathways of peptide generation.
Ciudad MT; Sorvillo N; van Alphen FP; Catalán D; Meijer AB; Voorberg J; Jaraquemada D
J Leukoc Biol; 2017 Jan; 101(1):15-27. PubMed ID: 27365532
[TBL] [Abstract][Full Text] [Related]
5. Naturally processed HLA class II peptides reveal highly conserved immunogenic flanking region sequence preferences that reflect antigen processing rather than peptide-MHC interactions.
Godkin AJ; Smith KJ; Willis A; Tejada-Simon MV; Zhang J; Elliott T; Hill AV
J Immunol; 2001 Jun; 166(11):6720-7. PubMed ID: 11359828
[TBL] [Abstract][Full Text] [Related]
6. Molecular determinants of peptide binding to two common rhesus macaque major histocompatibility complex class II molecules.
Dzuris JL; Sidney J; Horton H; Correa R; Carter D; Chesnut RW; Watkins DI; Sette A
J Virol; 2001 Nov; 75(22):10958-68. PubMed ID: 11602736
[TBL] [Abstract][Full Text] [Related]
7. The N-terminal six residues of peptide core sequences suffice for binding to HLA-DR4 (DRB1*0405) and DR9 (DRB1*0901) molecules.
Matsushita S; Fujisao S; Nishimura Y
Immunol Lett; 1997 Jul; 58(2):89-93. PubMed ID: 9271318
[TBL] [Abstract][Full Text] [Related]
8. Large scale mass spectrometric profiling of peptides eluted from HLA molecules reveals N-terminal-extended peptide motifs.
Escobar H; Crockett DK; Reyes-Vargas E; Baena A; Rockwood AL; Jensen PE; Delgado JC
J Immunol; 2008 Oct; 181(7):4874-82. PubMed ID: 18802091
[TBL] [Abstract][Full Text] [Related]
9. Specific and general HLA-DR binding motifs: comparison of algorithms.
Borrás-Cuesta F; Golvano J; García-Granero M; Sarobe P; Riezu-Boj J; Huarte E; Lasarte J
Hum Immunol; 2000 Mar; 61(3):266-78. PubMed ID: 10689116
[TBL] [Abstract][Full Text] [Related]
10. The Dendritic Cell Major Histocompatibility Complex II (MHC II) Peptidome Derives from a Variety of Processing Pathways and Includes Peptides with a Broad Spectrum of HLA-DM Sensitivity.
Clement CC; Becerra A; Yin L; Zolla V; Huang L; Merlin S; Follenzi A; Shaffer SA; Stern LJ; Santambrogio L
J Biol Chem; 2016 Mar; 291(11):5576-5595. PubMed ID: 26740625
[TBL] [Abstract][Full Text] [Related]
11. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.
Mandic M; Castelli F; Janjic B; Almunia C; Andrade P; Gillet D; Brusic V; Kirkwood JM; Maillere B; Zarour HM
J Immunol; 2005 Feb; 174(3):1751-9. PubMed ID: 15661941
[TBL] [Abstract][Full Text] [Related]
12. Release of DR molecules from complexes with invariant chain through the formation of a C-terminal 25 kDa invariant chain fragment.
Demotz S; Danieli C
Mol Immunol; 1993 Dec; 30(18):1623-32. PubMed ID: 8272076
[TBL] [Abstract][Full Text] [Related]
13. Functional HLA-DM on the surface of B cells and immature dendritic cells.
Arndt SO; Vogt AB; Markovic-Plese S; Martin R; Moldenhauer G; Wölpl A; Sun Y; Schadendorf D; Hämmerling GJ; Kropshofer H
EMBO J; 2000 Mar; 19(6):1241-51. PubMed ID: 10716924
[TBL] [Abstract][Full Text] [Related]
14. Naturally processed peptides from two disease-resistance-associated HLA-DR13 alleles show related sequence motifs and the effects of the dimorphism at position 86 of the HLA-DR beta chain.
Davenport MP; Quinn CL; Chicz RM; Green BN; Willis AC; Lane WS; Bell JI; Hill AV
Proc Natl Acad Sci U S A; 1995 Jul; 92(14):6567-71. PubMed ID: 7604034
[TBL] [Abstract][Full Text] [Related]
15. Evolutionary conservation of major histocompatibility complex-DR/peptide/T cell interactions in primates.
Geluk A; Elferink DG; Slierendregt BL; van Meijgaarden KE; de Vries RR; Ottenhoff TH; Bontrop RE
J Exp Med; 1993 Apr; 177(4):979-87. PubMed ID: 8459225
[TBL] [Abstract][Full Text] [Related]
16. Allele specificity of structural requirement for peptides bound to HLA-DRB1*0405 and -DRB1*0406 complexes: implication for the HLA-associated susceptibility to methimazole-induced insulin autoimmune syndrome.
Matsushita S; Takahashi K; Motoki M; Komoriya K; Ikagawa S; Nishimura Y
J Exp Med; 1994 Sep; 180(3):873-83. PubMed ID: 8064238
[TBL] [Abstract][Full Text] [Related]
17. Increased diversity of the HLA-B40 ligandome by the presentation of peptides phosphorylated at their main anchor residue.
Marcilla M; Alpízar A; Lombardía M; Ramos-Fernandez A; Ramos M; Albar JP
Mol Cell Proteomics; 2014 Feb; 13(2):462-74. PubMed ID: 24366607
[TBL] [Abstract][Full Text] [Related]
18. Human B cells secrete migration inhibition factor (MIF) and present a naturally processed MIF peptide on HLA-DRB1*0405 by a FXXL motif.
Wymann D; Blüggel M; Kalbacher H; Blesken T; Akdis CA; Meyer HE; Blaser K
Immunology; 1999 Jan; 96(1):1-9. PubMed ID: 10233671
[TBL] [Abstract][Full Text] [Related]
19. Structural diversity of human class II histocompatibility molecules induced by peptide ligands.
Georges B; Loing E; Neveu R; Melnyk O; Gras-Masse H; Auriault C
FEBS Lett; 2000 Sep; 481(3):249-54. PubMed ID: 11007973
[TBL] [Abstract][Full Text] [Related]
20. HLA-DR1 (DRB1*0101) and DR4 (DRB1*0401) use the same anchor residues for binding an immunodominant peptide derived from human type II collagen.
Rosloniec EF; Whittington KB; Zaller DM; Kang AH
J Immunol; 2002 Jan; 168(1):253-9. PubMed ID: 11751969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
